Denmark. Demant A/S
| Date of agreement: | 17 Dec 2024 |
|---|---|
| Country: | Denmark |
| Customer: | Demant A/S |
| Amount in DKK: | DKK 745 million |
| Amount in EUR: | EUR 100 million |
| Maturity: | 7 years |
| NACE sector / loan type: | Health care sector |
Project
NIB provides an investment loan to co-finance part of Demant’s research and development (R&D) programme for the years 2024-2025.
The company will be focusing their R&D efforts primarily on developing new products and solutions, including the continued development of chipsets and audio processing algorithms, using AI and deep neural networks.
These R&D initiatives and products are expected to significantly improve products and solutions over time which will lead to an improvement in the quality of life for people living with hearing loss. The improved quality of life enables them to participate in social and professional environments, from where they might otherwise be excluded.
Demant is a leading global hearing healthcare company, with its headquarters in Denmark. The William Demant Foundation has the majority-ownership of the company. Demant’s offering ranges from hearing aids and hearing implants to diagnostic equipment, services and audio solutions. The company is listed on NASDAQ Copenhagen.
Fulfilment of NIB's mandate
Productivity and Environment
The investment loan represents continuity in the long-term cooperation between NIB and Demant, providing financing for the company’s R&D expenditures during 2024-2025.
Demant’s R&D investments continue to grow in line with the company’s turnover growth. Demant is planning to keep its R&D intensity, which currently stands at 6% (R&D expenditures compared to the revenue). Demant has a very dynamic product portfolio, which relies on R&D.
The company’s work in hearing technology is expected to help people with hearing loss to have a better quality of life. The technology enables them to be more involved with work life and social situations. This will also boost overall human capital development, as people with hearing impairments will be better able to contribute to society.
Demant is an integral part of Denmark’s robust MedTech cluster, maintaining strong collaborative relationships with both industry partners and academic institutions. These partnerships focus on developing advanced algorithms, improving eHealth solutions and researching cognitive health sience.
Impact indicators in relation to the investments:
- R&D intensity (R&D expenditure as a % of turnover)
Sustainability summary
NIB has not identified any significant environmental issues connected to the R&D programme.
